Status:
COMPLETED
Multimodal Managements for Metastatic Pancreatic Cancer.
Lead Sponsor:
Zhejiang University
Conditions:
Metastatic Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) remains a challenging malignancy, with over 300,000 patients diagnosed annually worldwide. Patients with metastatic pancreatic cancer (MPC) are generally not co...
Eligibility Criteria
Inclusion
- Adult patients aged ≥18 years (at diagnosis).
- Cytologically or histologically confirmed pancreatic adenocarcinoma.
- Synchronous liver metastatic disease (at diagnosis).
- No evidence of extrahepatic metastases (at diagnosis.)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.
- Eligible for multimodal treatment.
Exclusion
- Multi-organ metastatic pancreatic cancer.
- Contraindications to surgical resection or systemic treatment.
- Inability to participate in follow-up assessments.
- History of other malignancies.
- Refusal of treatment.
Key Trial Info
Start Date :
June 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2025
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT06967233
Start Date
June 1 2019
End Date
April 1 2025
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The first affiliated hospital, Zhejiang university school of medicine
Hangzhou, Zhejiang, China, 310000